Perennial Allergic Rhinitis (PAR)
Oncology·MeSH: Rhinitis, Allergic, Perennial
Prevalence
20000.0 / 100K
Incidence
2000.0 / 100K/yr
2 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| LY3650150 | ELI LILLY & Co (LLY) |
Phase 2(1)
| Drug | Company |
|---|---|
| Antiretroviral Therapy | ELI LILLY & Co (LLY) |
Compare drugs
Frequently asked questions
How many drugs are in development for Perennial Allergic Rhinitis (PAR)?
BioSniper tracks 2 drugs in development for Perennial Allergic Rhinitis (PAR) across 1 company.
How many clinical trials target Perennial Allergic Rhinitis (PAR)?
There are 1 clinical trial targeting Perennial Allergic Rhinitis (PAR) tracked by BioSniper.
What is the prevalence of Perennial Allergic Rhinitis (PAR)?
The estimated prevalence of Perennial Allergic Rhinitis (PAR) is approximately 20000.0 per 100,000 population.
Deep-dive into Perennial Allergic Rhinitis (PAR)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis